Management of Severe Onychomycosis and Symptomatic Tinea Pedis

Systemic Therapy Options

• The British Journal of Dermatology recommends itraconazole as first-line treatment for dermatophyte onychomycosis in patients who cannot tolerate terbinafine, with dosing at 200 mg daily for 12 weeks continuously, or pulse therapy at 400 mg daily for 1 week per month 1, 2
• Itraconazole should be taken with food and acidic beverages for optimal absorption, and hepatic function tests should be monitored, especially with concomitant use of statins 1, 2
• Common adverse effects of itraconazole include headache and gastrointestinal upset 1
• The British Journal of Dermatology suggests caution with statins, as concurrent use with itraconazole may increase statin levels 3
• Fluconazole is an alternative systemic option, with dosing at 150-450 mg once weekly for at least 6 months for toenail infections, and may have fewer drug interactions with statins than itraconazole 2, 4

Topical Therapy Options

• The British Journal of Dermatology recommends using topical antifungal treatments as adjunct to systemic therapy or for mild cases of onychomycosis 1
• Amorolfine 5% lacquer can be applied once or twice weekly for 6-12 months, and ciclopirox 8% lacquer can be applied once daily for up to 48 weeks 2
• For tinea pedis, antifungal creams or solutions such as miconazole, clotrimazole, or tolnaftate can be applied to affected areas 1, 3

Preventive Measures

• The British Journal of Dermatology suggests discarding old contaminated footwear if possible, or decontaminating shoes with naphthalene mothballs 1, 3
• Applying antifungal powders inside shoes regularly and considering spraying terbinafine solution into shoes periodically can help prevent reinfection 1, 3
• Keeping nails short and clean, wearing cotton absorbent socks, using antifungal powders on feet, and avoiding sharing nail clippers can help prevent tinea pedis 3

Monitoring and Follow-up

• The British Journal of Dermatology recommends monitoring for at least 48 weeks from start of treatment to identify potential relapse 5
• Assessment should include both clinical improvement and mycological cure (negative microscopy and culture) 5

Special Considerations

• Dermatophytoma may require mechanical removal before antifungal therapy 6
• Thick nails may respond poorly to treatment, and nail debridement may be necessary 6
• Treatment failure can occur due to high recurrence rates, and complete eradication may require extended therapy 6
• Drug interactions between antifungals and statins should be carefully monitored, and temporary dose adjustment of rosuvastatin may be necessary 4

Pulse Dose Regimen for Onychomycosis

Itraconazole Pulse Dosing Specifics

• The British Journal of Dermatology recommends administering 400 mg of itraconazole daily (200 mg twice daily) for 1 week per month, with 2 pulses recommended for fingernails and 3 pulses for toenails 7
• The total treatment time for itraconazole pulse therapy is 2 months for fingernails and 3 months for toenails, as recommended by the British Journal of Dermatology 8
• Itraconazole must be taken with food and acidic beverages for optimal absorption, according to the British Journal of Dermatology 7

Monitoring Requirements

• The British Journal of Dermatology recommends baseline liver function tests before initiating itraconazole therapy, as well as monitoring hepatic function tests in patients with pre-existing deranged results 7
• Hepatic function tests should be monitored when receiving continuous therapy for more than one month, as advised by the British Journal of Dermatology 7
• The British Journal of Dermatology also recommends monitoring hepatic function tests with concomitant use of hepatotoxic drugs, including statins 7

Important Contraindications and Cautions

• The British Journal of Dermatology states that itraconazole is contraindicated in patients with heart failure due to negative inotropic effects 7
• Itraconazole is also contraindicated in patients with hepatotoxicity or active liver disease, according to the British Journal of Dermatology 7

Special Populations

• The British Journal of Dermatology recommends a pediatric dosing regimen of 5 mg/kg per day for 1 week every month, with 2 months (2 pulses) for fingernail infection and 3 months (3 pulses) for toenail infection 8
• The clinical cure rate for pediatric patients with itraconazole pulse therapy is 94%, as reported by the British Journal of Dermatology 8
• For Candida onychomycosis, the British Journal of Dermatology recommends itraconazole as the first-line treatment, with a pulse regimen of 400 mg per day for 1 week per month 9
• The minimum treatment duration for Candida onychomycosis is 4 weeks for fingernails and 12 weeks for toenails, according to the British Journal of Dermatology 9
• Itraconazole has a superior cure rate compared to terbinafine for Candida infections, with 92% vs 40% cure rates, as reported by the British Journal of Dermatology 9

Clinical Pearls

• The British Journal of Dermatology suggests considering combination therapy with topical antifungals, such as amorolfine or ciclopirox, for enhanced efficacy 8

Treatment of Onychomycosis

Introduction to Treatment Options

• The British Journal of Dermatology recommends that terbinafine persists in nails for 6 months after treatment completion due to its long half-life 10
• Amorolfine 5% lacquer is applied once or twice weekly for 6-12 months, as reported by the British Journal of Dermatology 10
• Ciclopirox 8% lacquer shows 34% mycological cure vs 10% with placebo, but clinical cure is only 8% vs 1%, according to the British Journal of Dermatology 10
• Efinaconazole 10% shows mycological cure rates approaching 50% and complete cure in 15% after 48 weeks, as stated in the British Journal of Dermatology 10
• Griseofulvin is not recommended as first-line treatment due to lower efficacy (30-40% mycological cure), long treatment duration (12-18 months for toenails), and higher relapse rates, as noted in the British Journal of Dermatology 10

Fluconazole Regimen for Severe Tinea Pedis and Onychomycosis in Elderly Patients

Recommended Fluconazole Dosing

• For an elderly patient intolerant of terbinafine with severe tinea pedis and onychomycosis, fluconazole 450 mg once weekly for at least 6 months is the recommended systemic regimen, as suggested by the British Journal of Dermatology 11
• The 450 mg weekly dose is specifically recommended for toenail infections, with treatment duration of at least 6 months, according to the British Journal of Dermatology 11

Baseline Monitoring Requirements

• Obtain baseline liver function tests and complete blood count before initiating fluconazole therapy, as recommended by the British Journal of Dermatology 11
• Monitor liver function tests during high-dose or prolonged therapy, as suggested by the British Journal of Dermatology 11

Essential Adjunctive Treatments

Topical Antifungal Therapy

• Combine systemic fluconazole with topical antifungal lacquers to enhance cure rates and provide antimicrobial synergy, as recommended by the British Journal of Dermatology 12
• Amorolfine 5% lacquer can be applied once or twice weekly for 6-12 months to affected nails, according to the British Journal of Dermatology 11
• Ciclopirox 8% lacquer can be applied once daily for up to 48 weeks as an alternative, as suggested by the British Journal of Dermatology 11
• Combination of topical and systemic treatments provides wider antifungal spectrum, improved fungicidal activity, increased cure rates, and suppression of resistant mutants, according to the British Journal of Dermatology 12

Footwear Decontamination

• Decontaminate or replace contaminated footwear to eliminate fungal reservoirs, as recommended by the British Journal of Dermatology 11
• Place naphthalene mothballs in shoes and seal in plastic bags for minimum 3 days to kill fungal arthroconidia, as suggested by the British Journal of Dermatology 11
• Apply antifungal powders inside shoes regularly after decontamination, according to the British Journal of Dermatology 11
• Consider periodic spraying of terbinafine solution into shoes, as recommended by the British Journal of Dermatology 11

Important Clinical Caveats

Drug Interaction Considerations

• Review all concurrent medications for potential interactions, as suggested by the British Journal of Dermatology 11
• Itraconazole may not be suitable for elderly patients due to contraindication in heart failure, which is more prevalent in elderly populations, according to the British Journal of Dermatology 11
• Itraconazole may not be suitable for elderly patients due to greater potential for drug interactions with statins and other medications commonly used by elderly patients, as recommended by the British Journal of Dermatology 12

Guideline for the Management of Onychomycosis

Diagnosis and Etiology

• Obtain mycological confirmation (microscopy and culture) before initiating therapy because only about 50 % of nail dystrophies are fungal 13.
• Dermatophytes are responsible for the vast majority of onychomycosis cases, with Trichophyton rubrum being the most common species 14.
• Yeasts and non‑dermatophyte molds are frequently secondary colonizers or saprophytes in previously damaged nails 14, 13.

First‑Line Systemic Therapy – Terbinafine

• Terbinafine is the first‑line oral agent for dermatophyte onychomycosis, achieving cure rates of 70‑80 % for toenails and 80‑90 % for fingernails 14, 13.
• It demonstrates superior in‑vitro and in‑vivo activity compared with all other antifungal agents for dermatophyte infections 14, 13.
• Dosing: 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails) 15.
• Baseline monitoring: Perform liver function tests (LFTs) and a complete blood count (CBC) before starting therapy 15.
• Safety: Idiosyncratic hepatotoxicity is rare; reversible taste disturbance occurs in ≈1 in 400 patients 16.
• Drug interactions: Rifampicin reduces terbinafine plasma levels; cimetidine increases them 16.
• Contraindication: Significant hepatic impairment 15.

Second‑Line Systemic Therapy – Itraconazole

• Itraconazole is indicated when terbinafine is contraindicated, not tolerated, or when treating Candida onychomycosis 14, 13.
• Critical drug interactions: Contraindicated with terfenadine, astemizole, sertindole, midazolam, and cisapride due to enhanced toxicity 16; it also raises levels of warfarin, digoxin, ciclosporin, and simvastatin (increasing myopathy risk) 16.
• Contraindication: Pregnancy 16.

Third‑Line Systemic Therapy – Fluconazole

• Fluconazole is considered when both terbinafine and itraconazole are unsuitable 15.
• Dosing: 12‑16 weeks for fingernail infections and 18‑26 weeks for toenail infections 15.
• Monitoring: Baseline LFTs and CBC, with repeat testing during high‑dose or prolonged courses 15.

Topical Antifungal Options (Adjunct or Mild Disease)

• Amorolfine 5 % lacquer applied once or twice weekly for 6‑12 months yields an approximate 50 % cure rate for distal infections 16.

Candida Onychomycosis

• Itraconazole is the preferred agent for Candida nail infections, achieving cure rates of 92 % versus 40 % with terbinafine 14.

Monitoring, Follow‑Up, and Outcome Assessment

• Patients should be followed for at least 48 weeks (preferably 72 weeks) from treatment initiation to detect relapse 14, 13.
• End‑of‑therapy culture is recommended, especially in high‑risk groups, to confirm mycological clearance 15.
• Mycological cure rates are typically ~30 % higher than clinical cure rates; complete nail normalization may lag behind eradication 17.

Treatment Failure and Management

• Even with optimal terbinafine therapy, a consistent failure rate of 20‑30 % is observed 14, 13.
• Common contributors to failure include poor patient compliance, inadequate drug absorption, immunosuppression, and subungual dermatophytoma obstructing drug penetration 14, 13, 15.
• Management strategies: reassess adherence and diagnosis, consider alternative systemic agents, or perform partial nail avulsion for subungual dermatophytoma; complete nail avulsion can achieve near‑100 % cure in selected cases 14, 13.

Agents Not Recommended as First‑Line

• Griseofulvin is discouraged as a first‑line option because it yields low mycological cure rates (30‑40 %), requires prolonged treatment (12‑18 months for toenails), and is associated with higher relapse rates 16.

Terbinafine Dosing, Monitoring, and Alternatives for Adult Toenail Onychomycosis

First‑Line Systemic Therapy

• Terbinafine 250 mg once daily for 12 weeks is the first‑line regimen for dermatophyte toenail onychomycosis in adults, achieving mycologic cure rates of approximately 70‑80 %. 18
• For severe infections with extensive nail involvement, the treatment duration may be extended to 16 weeks. 18

Pediatric Weight‑Based Dosing (Off‑Label)

• Children 1–12 years with toenail onychomycosis:
  
  • < 20 kg → 62.5 mg daily for 12 weeks
  • 20–40 kg → 125 mg daily for 12 weeks
  • > 40 kg → 250 mg daily for 12 weeks (adult dose)
    These doses are derived from the same evidence base as adult therapy*. 18

Baseline and Ongoing Laboratory Monitoring

• Before initiating terbinafine, obtain baseline liver function tests (ALT, AST) and a complete blood count. 18
• Ongoing monitoring is advised for patients with any of the following: prior hepatitis or liver disease, heavy alcohol consumption, concurrent hepatotoxic medications, or pre‑existing abnormal liver enzymes. 18

Second‑Line Systemic Therapy – Itraconazole

• Continuous dosing: 200 mg daily for 12 weeks; Pulse dosing: 400 mg daily for 1 week per month for three cycles (total 3 months). 18
• Itraconazole should be taken with food and acidic beverages to optimize absorption. 18
• Contraindicated in patients with heart failure due to negative inotropic effects. 18
• Baseline and periodic hepatic function monitoring are required. 18

Third‑Line Systemic Therapy – Fluconazole

• Dose: 150–450 mg once weekly for a minimum of 6 months. 18
• Baseline liver function tests and complete blood count are required, with continued hepatic monitoring during high‑dose or prolonged therapy. 18

Safety Profile of Terbinafine

• Common adverse effects: gastrointestinal upset (nausea, diarrhea, abdominal pain), headache, reversible taste disturbance (≈ 1 in 400 patients). 18
• Less common/serious effects: aggravation of psoriasis, subacute lupus‑like syndrome, and rare but severe reactions such as Stevens‑Johnson syndrome and toxic epidermal necrolysis. 18

Drug‑Drug Interaction Considerations

• Terbinafine has relatively few interactions; however:
  
  • Rifampicin can lower terbinafine plasma concentrations.
  • Cimetidine can increase terbinafine levels.
  • Potential interaction with drugs metabolized by CYP2D6 (certain antidepressants, β‑blockers, antiarrhythmics). 18

Adjunctive Topical Antifungal Therapy

• Amorolfine 5 % lacquer applied once or twice weekly for 6–12 months enhances overall cure rates. 18
• Ciclopirox 8 % lacquer applied once daily for up to 48 weeks provides additional antifungal coverage. 18

Clinical Caveats and Decision Points

• Mycologic confirmation (microscopy and culture) is essential before starting systemic therapy, as only about 50 % of nail dystrophies are fungal. 18
• Terbinafine is markedly less effective against Candida onychomycosis (≈ 40 % cure) compared with itraconazole (≈ 92 % cure); itraconazole is therefore preferred for Candida infections. 18
• Continuous daily dosing of terbinafine yields superior outcomes compared with intermittent or pulse regimens. 18

Guideline for Management of Candida albicans Nail Infections

Diagnosis and Assessment

• Obtain mycological confirmation (microscopy and culture) before initiating any systemic antifungal therapy for nail disease. This prevents unnecessary treatment of non‑fungal nail dystrophies. 19
• Differentiate Candida paronychia (infection of the nail fold) from true Candida onychomycosis (invasion of the nail plate). The distinction is critical because therapeutic approaches differ markedly. 19

Treatment of Candida Paronychia (No Nail‑Plate Invasion)

• First‑line therapy is topical imidazole (clotrimazole or miconazole) applied to the affected nail folds. 19
• If a bacterial co‑infection is suspected, alternate the antifungal lotion with a topical antibacterial agent. 19
• Continue topical application until cuticle integrity is restored, which may require several months. 19
• Use broad‑spectrum, colorless, non‑sensitizing antiseptics that can be washed beneath the cuticle to sterilize the sub‑cuticular space. 19

Systemic Therapy for Candida Onychomycosis (Nail‑Plate Invasion)

• Itraconazole is the first‑line systemic agent. Pulse therapy is given at 400 mg daily (200 mg twice daily) for 1 week per month for 2 months in fingernail disease or for 3–4 months in toenail disease. This regimen provides the highest cure rates for Candida nail infections. 19

Drug Interactions and Safety

• Itraconazole markedly increases serum concentrations of warfarin, digoxin, ciclosporin, and simvastatin. Dose adjustments or close therapeutic monitoring are required when these agents are co‑prescribed. 20

Treatment Duration and Common Pitfalls

• Premature discontinuation of itraconazole leads to treatment failure; the full prescribed pulse course must be completed. 19
• Yeasts often colonize nails that have been previously damaged; clinicians should address underlying nail trauma or chronic paronychia to prevent recurrence. 19